These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 9593590)

  • 1. Sensitization to the conditioned rewarding effects of morphine and cocaine: differential effects of the kappa-opioid receptor agonist U69593.
    Shippenberg TS; LeFevour A; Thompson AC
    Eur J Pharmacol; 1998 Mar; 345(1):27-34. PubMed ID: 9593590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. kappa-Opioid receptor agonists prevent sensitization to the conditioned rewarding effects of cocaine.
    Shippenberg TS; LeFevour A; Heidbreder C
    J Pharmacol Exp Ther; 1996 Feb; 276(2):545-54. PubMed ID: 8632320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single cocaine exposure enhances both opioid reward and aversion through a ventral tegmental area-dependent mechanism.
    Kim JA; Pollak KA; Hjelmstad GO; Fields HL
    Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5664-9. PubMed ID: 15064402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased responsiveness of mesolimbic and mesostriatal dopamine neurons to cocaine following repeated administration of a selective kappa-opioid receptor agonist.
    Heidbreder CA; Schenk S; Partridge B; Shippenberg TS
    Synapse; 1998 Nov; 30(3):255-62. PubMed ID: 9776129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the kappa-opioid receptor agonist U-50,488 on morphine-induced place preference conditioning in the developing rat.
    Bolanos CA; Garmsen GM; Clair MA; McDougall SA
    Eur J Pharmacol; 1996 Dec; 317(1):1-8. PubMed ID: 8982712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the kappa-opioid receptor agonist, U69593, on the development of sensitization and on the maintenance of cocaine self-administration.
    Schenk S; Partridge B; Shippenberg TS
    Neuropsychopharmacology; 2001 Apr; 24(4):441-50. PubMed ID: 11182539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of mesolimbic kappa-opioid systems in the discriminative stimulus effects of morphine.
    Spanagel R; Shoaib M
    Neuroscience; 1994 Dec; 63(3):797-804. PubMed ID: 7898679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reinstatement of extinguished drug-taking behavior in rats: effect of the kappa-opioid receptor agonist, U69593.
    Schenk S; Partridge B; Shippenberg TS
    Psychopharmacology (Berl); 2000 Jul; 151(1):85-90. PubMed ID: 10958121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissociable effects of the kappa-opioid receptor agonists bremazocine, U69593, and U50488H on locomotor activity and long-term behavioral sensitization induced by amphetamine and cocaine.
    Vanderschuren LJ; Schoffelmeer AN; Wardeh G; De Vries TJ
    Psychopharmacology (Berl); 2000 May; 150(1):35-44. PubMed ID: 10867974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of pre- and postsynaptic dopamine D2 receptor function by the selective kappa-opioid receptor agonist U69593.
    Acri JB; Thompson AC; Shippenberg T
    Synapse; 2001 Mar; 39(4):343-50. PubMed ID: 11169785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the kappa-opioid receptor agonist, U69593, on reinstatement of extinguished amphetamine self-administration behavior.
    Schenk S; Partridge B
    Pharmacol Biochem Behav; 2001 Apr; 68(4):629-34. PubMed ID: 11526958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitization to the conditioned rewarding effects of morphine: pharmacology and temporal characteristics.
    Shippenberg TS; Heidbreder C; Lefevour A
    Eur J Pharmacol; 1996 Mar; 299(1-3):33-9. PubMed ID: 8901005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of the neurotoxic effects of methamphetamine by the selective kappa-opioid receptor agonist U69593.
    El Daly E; Chefer V; Sandill S; Shippenberg TS
    J Neurochem; 2000 Apr; 74(4):1553-62. PubMed ID: 10737612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kappa opioid inhibition of morphine and cocaine self-administration in rats.
    Glick SD; Maisonneuve IM; Raucci J; Archer S
    Brain Res; 1995 May; 681(1-2):147-52. PubMed ID: 7552272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The delta-opioid receptor antagonist naltrindole prevents sensitization to the conditioned rewarding effects of cocaine.
    Shippenberg TS; Heidbreder C
    Eur J Pharmacol; 1995 Jun; 280(1):55-61. PubMed ID: 7498254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kappa-opioid agonist U69593 potentiates locomotor sensitization to the D2/D3 agonist quinpirole: pre- and postsynaptic mechanisms.
    Perreault ML; Graham D; Bisnaire L; Simms J; Hayton S; Szechtman H
    Neuropsychopharmacology; 2006 Sep; 31(9):1967-81. PubMed ID: 16237381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cotreatment with the kappa opioid agonist U69593 enhances locomotor sensitization to the D2/D3 dopamine agonist quinpirole and alters dopamine D2 receptor and prodynorphin mRNA expression in rats.
    Perreault ML; Graham D; Scattolon S; Wang Y; Szechtman H; Foster JA
    Psychopharmacology (Berl); 2007 Nov; 194(4):485-96. PubMed ID: 17619861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking.
    Schenk S; Partridge B; Shippenberg TS
    Psychopharmacology (Berl); 1999 Jun; 144(4):339-46. PubMed ID: 10435406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential modification of the rewarding effects of methamphetamine and cocaine by opioids and antihistamines.
    Masukawa Y; Suzuki T; Misawa M
    Psychopharmacology (Berl); 1993; 111(2):139-43. PubMed ID: 7870944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conditioned place preference: no tolerance to the rewarding properties of morphine.
    Contarino A; Zanotti A; Drago F; Natolino F; Lipartiti M; Giusti P
    Naunyn Schmiedebergs Arch Pharmacol; 1997 May; 355(5):589-94. PubMed ID: 9151297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.